Clinical Trial

HTL0039732 in Participants With Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-07-05; most recent amendment 2025-06-05.
Trial Details
NCT Number NCT05944237
Lead Sponsor Cancer Research UK
Collaborators: Nxera Pharma UK Limited
Conditions Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms +6 more
Enrollment 150 participants
Start Date 2023-07-13
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-08